T505543int 17/10/05 14:42 Page 1

BIOTECH IN WALLONIA  REPORT 2005 T505543int 17/10/0514:42Page2 2 La Biotechnologie en wallonie - Rapport 2002 C OVER : GlaxoSmithKline Biologicals TABLE OFCONTENTS T505543int 17/10/0514:42Page3 3.2 3.1 3 2.4 2.3 2.2 2.1 2 1 MAIN ADDRESSES ABBREVIATIONS USEFUL INFORMATION TIME TOHARVEST EXCELLENCE ININCENTIVES EXCELLENCE INRESEARCH:THEBIOTECHNOPOLES WALLONIA: AREGION FORGROWTHANDSUCCESS ENVIRONMENT AGRI-FOOD CONTRACT MANUFACTURING BIOINFORMATICS DRUG DISCOVERY SERVICES SERVICE ANDTECHNOLOGYPROVIDERS RESEARCH ANDPRODUCTIONINBIOLOGICALS DIAGNOSTIC TOOLSANDBIOMEDICALTECHNOLOGIES BIOPHARMACEUTICALS HEALTHCARE THE EXPANSION OFTHEBIOTECHINDUSTRY WALLONIA AT THECROSSROADSOFEUROPEANREGIONS FOREWORD 24 5 12 27 40 22 42 38 40 12 35 23 21 20 8 16 30 31 14 6 3 Biotech in Wallonia - Report 2005 T505543int 17/10/05 14:42 Page 4

"Beyond seeding inventions into innovative e T505543int 17/10/05 14:42 Page 5

FOREWORD

e enterprises, time for harvesting has come"

As soon as the first wave of biotechnology rose in Europe, the Wallonia Region saw an opportunity to enter this key sector.

The Walloon authorities started to help newborn companies to devise their strategic plans. Moreover, as these start-ups

were facing a highly competitive environment, the risk of “sudden death” was great. This did not deter the entrepreneurial

mind in Wallonia. On the contrary, biotechnology was chosen as a top priority sector to position the region at the forefront of

European Bio-regions. The existing chemical and pharmaceutical companies provided the industrial expertise necessary to

appreciate the results of the highly innovative research that was taking place in the universities. The life sciences sector

could now enter a new phase of development. The ambition of many of these entrepreneurs has since turned to a rapid

expansion and a shift of their activities towards the segments with the highest added values.

The Walloon Region can count on the Directorate General of Technology, Research and Energy (DGTRE), being the “one

stop-shop” for research in the region. The DGTRE continually updates its portfolio of grants and subsidies to stimulate inno-

vative research. It actively promotes the appeal of the Region with the help of the Wallonia Export and Foreign Investment

Agency (AWEX). These two agencies work in synergy to catalyze the development of this high growth/high value sector.

Together, they act as fertilizer that continues to improve the possibility of harvesting even more fruit!

PHOTO: Curvicladium cygneum (Unité de Microbiologie, UCL) T505543int 17/10/05 14:42 Page 6

Wallonia is one of the three regions in the Kingdom of WALLONIA Belgium, situated south of Brussels, Belgium’s capital city. The Walloon region is located at the center of a 400-km cir- AT THE CROSSROADS cle in Europe that encompasses London, Amsterdam, Paris, Strasbourg and Dusseldorf. Wallonia is home to OF EUROPEAN REGIONS Belgium’s French- and German-speaking communities. Its 3.34 million inhabitants live at the crossroads of the Germanic, Anglo-Saxon and Latin cultures. This central location and high level of cross-cultural fertilization explains the quality of the Wallonia entrepreneurial spirit.

The region represents 55% of the Belgian territory and con- tains most of the country’s natural resources like water and forests. Beautiful landscapes with valleys and rivers add to Wallonia’s enjoyable lifestyle, blending the Latin way of life with the rigor of northern Europe. Wallonia has one of the best travel networks in Europe. From high-speed trains to easy air connections for interna- tional travelers, and a dense highway network. Moreover, as optical cables have been laid along these highways, they have become true “Infobahn’s”, leading the region into the “digital age”.

According to official economic data, the service sectors predominate in Wallonia, comprising 73% of the regional gross added value and 76% of regional employment.

Wallonia is famous for the highly technical character of its products, though they are mainly considered traditional activities. In recent years, R&D expenditure has increased in the business sector so that it now exceeds the European Union (EU) average. Wallonia’s entrepreneurs have accu- mulated impressive know-how by concentrating on high growth niches in sectors like sciences, aerospace, biotech- nology, microelectronics, new material and information technology.

The region is actively building a strategy for research and innovation in order to promote technological development.

Biotech in Wallonia - Report 2005 Biotech in Wallonia Technology sectors accounted for 8.5 % of salaried employment in 2003, but recently, employment has been 16 T505543int 17/10/0514:42Page7 products. mechanical, engineering,chemicalandpharmaceutical are are devotedtotheEU.Itsmainexports exports Wallonia isalsowellintegratedintheEUasover75%ofits sion oftheregion’s productive base. tors, allofwhichcontributetothedevelopmentandexten- universities, research centers,andfinancialpublicsec- This “innovationsystem”isbasedoncollaborationbetween andlifescienceindustries. the pharmaceutical increasing rapidlyinhigh-techmanufacturingindustries,chiefly UNIVERSITY CENTRES SCIENTIFIC RESEARCH CENTRES TOURNAI FRANCE MONS NIVELLES BRUSSELS CHARLEROI LA-NEUVE LOUVAIN GEMBLOUX NAMUR WAVRE LIBRAMONT LONDON MARCHE PARIS BRUSSELS BASTOGNE LIEGE ARLON AMSTERDAM VERVIERS STRASBOURG KÖLN LUXEMBURG NETHERLANDS GERMANY 7 Biotech in Wallonia - Report 2005 T505543int 17/10/05 14:42 Page 8

In the 21st century, Wallonia’s biotechnology sector has renewed strength. Dynamic entrepreneurs and innovative research institutes have combined their efforts with local and regional agencies, namely, the Directorate General of Technology, Research and Energy (DGTRE), the Wallonia Export and Foreign Investment Agency (AWEX) and the important financial arm of the local authorities, the Société Regionale d’Investissement de Wallonie (SRIW). THE EXPANSION OF As a result of this cooperation, Wallonia has shown continu- ous revenue growth in its 69 biotechnology companies. The THE BIOTECH INDUSTRY turnover in 2003 amounts to € 2,376 million growing by more than 19 % since 2001.

Table 1 Biotech activity in Wallonia

1997 2001 2003 Increase (2001-2003)

Nbr. of companies 25 55 69 + 25 %

Revenues (mio €) 1,034 1,994 2,376 + 19 %

Nbr. of employees 3,034 4,461 5,227 + 17 %

“Source: Data collected and compiled by CRGB, Centre PME and Pi_ (ULg)”

The total number of companies increased from 55 to 69 due on the one hand to the creation of new companies (an increase of 10 since 2001), and on the other to the recent introduction of biotechnology activities in existing compa- nies (an increase of 4). This has helped the region take more than 80% of the country’s share of the biotechnology activity, as shown in table 2.

Table 2 Wallonia’s share of biotech activity in Belgium in 2003

Nbr. of Revenues Revenue Nbr. of Employees Companies (mio €) % of Total employees % of Total

Brussels 24 109 3.77 % 481 6.31 %

Flanders 39 403 13.95 % 1,912 25.09 %

Wallonia 69 2,376 82.27 % 5,227 68.60 %

Total 132 2,888 100 % 7,620 100 %

Biotech in Wallonia - Report 2005 Biotech in Wallonia “Source: Data collected and compiled by CRGB, Centre PME and Pi_ (ULg)” 28 T505543int 17/10/0514:42Page9 products worldwidefrom Belgium. Moreover, theyare localproducers anddistribute their eration withlocaluniversitiesandsmallerbiotechventures. grams, notonlyinternally, through coop- butalsoexternally sector intheregion. Theyinvestheavilyinresearch pro- Eurogentec Biologicals, BaxterHealthcare,UCBGroup global leadersintheirfield,thatis, The totalfigure includessuccessfulcompaniesthatare tional revenue. a keysource ofinnovativeproducts, andinevitablyaddi- products. Giventime,theyoungercompanieswillbecome when theirresearch programs developintomarketable the technologiesgeneratedbysmallinnovativeenterprises niche. Meanwhile,establishedcompaniesbenefitfrom andcreate theirown young companiesstrivetostart likebiotechwhere very This iseventruerinanindustry companies represent atleast80%oftotalrevenues. There isacommon“20/80”rulethatstatesthetop20 posted in2003. of theregional figure with GlaxoSmithKline Biologicalswhichcontributesto47% ofWalloniabiotech turnover comesfrom growth ofthesector. Thelargercontributioninthe neurial companiesare increasingly contributingtothe Interestingly the61small-andmedium-sizeentrepre- lished life-sciencesgroups basedintheregion. oflargeestab- This successisamplifiedbythesupport oa 923610%527100% 5,227 100 % Pi_ (ULg)” 2,376 “Source: DatacollectedandcompiledbyCRGB,Centre PMEand million, andnotmemberofalargecompanygroup. notexceeding SMEs: Lessthan250employees,annualturnover 69 Total SMEs Large Comparison betweenSMEandlargecompaniesin2003 Table 3 1622.4%23344.25% 2,313 25.34% 602 61 * b.o Rvne eeu b.o Employees Nbr. of Revenue Revenues (mio Companies Nbr. of ,7 46 ,1 55.75% 2,914 74.66% 1,774 8 . Theyare powerhousesthatstimulatetheentire € fTtlepoes%ofTotal employees ofTotal % ) € 1,132 millionrevenues GlaxoSmithKline and € 40 oa 923610%527100% 5,227 100% 2,376 69 “Source: Data collectedandcompiledbyCRGB,Centre PMEandPi_(ULg)” Total & Services Technology Environment Agri-bio Healthcare Biotech activitybysectorin2003 Table 4 those activeincattleselection orinenzymeproduction. of plantsare more dependentonconsumerchoicesthan ed inthisfield.Companiesinvolvedgeneticengineering biotechnology. Legislationenablesresearch tobe conduct- receptive tonovelfoodsandproducts derivedfrom the limited. Compared tootherEuropeans, Belgiansare quite However the“biotechapplications”inthissectorremain lands andforests. tries, andthisisalsotrueforWallonia withitslargefarm- ofthegross nationalproducttant part inEuropean coun- represents impor- The foodandagriculturalindustry avery management”. biotech techniquesusedinthelargeractivities“waste tional processes, figures provide onlythepercentage ofthe As “environmental biotechnology”isstillmixedwithtradi- cleanse waterandairofdifferent typesofpollutants. ed microorganisms torestore soiltoitsprevious stateorto and technologies.Bioremediation, forexample,usesselect- Biotechnology todayisintroducing more “eco-friendly”tools techniques. methods totreat wastebasedonchemicalormechanical Companies activeinthesectorhavebeguntodevelop ven bythepublicauthoritiesatEuropean level. and theincreased environmental protection directives dri- brought aboutbyindustrialpollution oftheconcerns borne “Waste management”isstillarelatively youngindustry the companiesandmore than80%oftheturnover. linked “Technology andServices”,comprisingtwo-thirds of The leadingsectorsremain “Healthcare” andtheclosely b.o Rvne eeu b.o Employees Nbr. of Revenue Revenues (mio Companies Nbr. of 21774 ,4 21.87% 1.34% 1,143 7.45% 70 12.78% 0.06% 177 668 15 12.88% 64.01% 12 3,346 306 79.04% 7 1,878 22 28 € fTtlepoes%ofTotal employees ofTotal % ) 9 Biotech in Wallonia - Report 2005 T505543int 17/10/05 14:42 Page 10

As indicated in table 5, Wallonia demonstrates from a Sectors European perspective a significant strength in stimulating The world of biotechnology is vast and includes many dif- the entrepreneurial mind of scientists and businessmen. ferent industries. Their potential applications cover a wide range of sectors like pharmaceutics, chemistry, agriculture,

Table 5 food production and processing and environment. Wallonia in Europe (2002) For the purpose of this report, four sectors have been dis- Year 2002 Europe (*) Wallonia % tinguished according to the kind of technologies and prod- Inhabitants (million) 385 3.4 0.88% ucts generated.

Biotech companies (number of) 1,878 63 3.35%

Employment (FTE) 82,124 4,969 6.05% 1. Healthcare ❚ Biopharmaceuticals (*) Ernst & Young, ENDURANCE: The European Biotechnology Report 2003 ❚ (analysis year 2002) Diagnostics and medical technologies ❚ Biological research

With less than one percent of the European population, the 2. Service and Technology Providers Walloon Region compares favorably with other European ❚ Drug discovery services countries. With 4,969 people employed in the sector in ❚ Bioinformatics 2002, Wallonia boasts biotech revenues of € 2,295 million ❚ Contract manufacturers generated by 63 life science companies. This development ❚ Reagents suppliers is favored by the presence of 7 university centers and 5 science parks active in the field of biotechnology. 3. Agri-food ❚ Plants and animals The beginning of the 21st century meets ❚ Novel foods and ingredients the promises. 4. Environment The presence of highly qualified scientists and skilled tech- nicians enables Wallonia to attract investment in research centers and production facilities. Creation of new compa- nies, mergers and acquisitions, and management buy-outs contribute to the strengthening of the biotech sector in the

region. PHOTO: Molecular structure of cytochrome B562 of E.Coli (CBMN, FUSAGx) T505543int 17/10/05 14:42 Page 11

Table 6 Relevant Biotech Events since 2002

2003 January Creation of Phytesia, a spin-off from the University of Liège

2003 May Acquisition of an oligonucleotide production facility in San Diego by Eurogentec

2003 May Henogen acquires 4C Biotech, € 5 million investment for new cGMP facility

2003 July Implantation of Wetlands Engineering in the Louvain-la-Neuve Science Park

2003 August Move of the Eurogentec's production to a brand new building in the Liège Science Park

2003 August Implantation of OncoMethylome Sciences in Liège

2003 August IBA creates a joint venture with Schering AG to supply FDG for PET imaging in the UK

2003 October Creation of BioXpr, a spin-off from the University of Namur

2003 October Start of the GIGA technical facilities

2003 November Set-up of KitoZyme’s pilot plant in Liège

2003 November Euroscreen received "Belgium's Entrepreneur of the Year 2003" Trophy

2004 January After Boston, the Florida Proton Therapy Institute in Jacksonville, Florida, USA opts for the IBA system

2004 March Creation of Aseptic Technologies (spin-out of GSK Biologicals) in Crealys

2004 March GSK Biologicals investment of € 450 million in Wavre (new plant and QC center)

2004 April Wetlands becomes SME leader of an integrated project of the European FP6

2004 May Creation of DNAVision in Aeropole (Charleroi)

2004 June UCB Bioproducts successfully supplies peptidic active pharmaceutical ingredient for a commercial drug (cardio vascular)

2004 June Henogen achieves successful phase II clinical trial on new subunit vaccine against infectious mononucleosis

2004 October Coris BioConcept receives “Wallonia Prize for Exportation”

2004 December Henogen acquires Dutch spin-off biotech company ImmunoToko

2005 January Creation of Institute of Medical Immunology (IMI) in Aeropole (partnership between GSK Biologicals, the University of Brussels and the Wallonia Region)

2005 January Creation of Straticell in Namur

2005 January Creation of Viridaxis, a University of Louvain spin-off

2005 February Cardio3, specialized in stem cell cellular therapy, launches its activity in Braine-l'Alleud

2005 September UCB Bioproducts invests in significant additional cGMP peptide production capacities and capabilities to be fully operational in September 2005

11 T505543int 17/10/0514:42Page12 12 Biotech in Wallonia - Report 2005 they are active at the international level. they are activeattheinternational and development,production andcommercial divisionsas Companies inthehealthcare sectorusuallyfeature research tides, labeledcompounds,separationtools,andsoforth. for research andproduction, namely, oligonucleotides,pep- The third sectoris“research tools”andconsistsofproducts ments. tor andincludesdiagnostictoolsbiomedicalinstru- “Diagnostics andmedicaltechnologies”isthesecondsec- recombinant proteins, genetherapy, vaccinesandsoon. different therapiesbasedorderivedfrom biotechnology: anditencompasses The firstsectoris“biopharmaceuticals” & biomedicineandresearch tools. We havechosen todistinguishtherapyfrom diagnostics throughout theworld’s healthcare field. in 2000andtriggered awaveofcompanycreation The “HumanGenomeProject” produced itsfirstresults biotechnology. care isthesectorbenefitingmostfrom advancesin countless newdiagnosticsandresearch tools,health- worldwideand With more than400biopharmaceuticals HEALTHCARE 2 1 P which represents second. 35vaccinedosesdistributed every enjoyed ahealthy23%share oftheworldvaccinemarket, 20 kmsouth-eastofBrussels.In2002,GSKBiologicals Biologicals human vaccinesubsidiary, renamed has strengthened theleadershippositionofglobal The mergerofGlaxoWellcome withSmithKlineBeecham GlaxoSmithKline Biologicals BIOPHARMACEUTICALS HOTO : Cellular division("GênesetEthique"Pass ©BeneluxPress) (GSK Biologicals).Theyare basedinRixensart, GlaxoSmithKline T505543int 17/10/0514:42Page13 4. 2. 1. program: GSK Biologicalsfeatures anextremely ambitiousresearch European expertise, universitiesandtoitsstrong internal Thanks totheextensivecooperationwithBelgianand cines. Itnowhasmore than4,000employees. development, clinicaltrialsandproduction ofhumanvac- andWavrelocated inRixensart andfocusonresearch and since 2001.Mostofthecompany’s activities(90%)are of£1,147million,steadilyincreasing ata13%rate turnover 1989 andGlaxoWellcome in2000,achievedarecord after thesuccessivemergersofSmithKlinewithBeechamin In 2003,theBelgiamcompanyrenamed GSKBiologicals, the company’s successstory. boosted thevaccinologyresearch andwasatthesource of (Engerix-B againstHepatitisB,produced inyeast)which vaccine forhumanusemadebygeneticengineering human vaccines.In1986,SmithKline-RITlaunchedthefirst and builtitintoaglobalvaccinepowerhousefocusingon recognized thecompany’s potential,acquired thebusiness, a strong globalpartner. SmithKline&French from theUS purposes.In1963,theBelgiancompanylookedfor erinary research program wasdevelopedforbothhumanandvet- in1956andanambitiousvaccine cine activitystarted RIT company, producing antibiotics.Thevac- whichstarted beganin1945withthecreation ofthe This successstory antigens fromantibioticstorecombinant Success story: With the25products inthepipeline in2003and20clini- cancer. results inthefieldofvaccinesagainstmalariaandcervical In 2004,GSKBiologicalshasachievedpromising clinical specific immuneresponses. prostate cancer. against severalcancers:melanoma,lung,breast and ortherapeutic vaccineswhichfight 3. “Pharmaccines” tis, malaria,HIV, tuberculosis, dengue,rotavirus, andsoon. the WHO,PAHO andUNICEF:HBV, poliomyelitis,meningi- varicella zostervirus. against S.PneumoniaeinfectionandRSV, influenzaand HPV viruses,adultandtravelersvaccines,elderlyvaccines vaccines againstcervicalcanceressentiallycausedby S. Pneumoniae,meningitis,rotavirus infections,adolescent Development ofnewadjuvantstoincrease/modulate Vaccines forthedevelopingworldincooperationwith Vaccines for“alllifestages”:paediatricvaccinesagainst stances stemmingfrom research. role inthedevelopmentofbiologicallyactivesub- important employees, ofwhomtwothirds workonR&D,playsan located intheLouvain-la-NeuveScienceParkwith355 this resolute R&Dstrategy, the world-wide toResearch andDevelopment.Inthecontextof ofitsresourcesEli Lilly&Companydevotesamajorpart Eli Lilly tives. This investments initsEuropean production unitofbloodderiva- Located inLessines, Baxter Healthcare cal advances. pany steadilyremains attheforefront thelatesttechnologi- ter basedinthenearbycityofNivelleswillensure thecom- capacities, a165-scientistresearch anddevelopmentcen- In additiontothissignificantinvestmentinproduction 1,300 persons. 10% increase inemploymentfrom 1,134uptoclose and theWallonia Region(20%),willbeaccompaniedbya products. aninnovativeasepticfillingofvialswithinjectable form Technologies nological development.Itsfirstspin-out( GSK Biologicalsalsoplaysakeyrole intheregional tech- Region andtheUniversityofBrussels. oftheWalloniaAeropole ofGosselies,withthepartnership “Institute forMedicalImmunology”(IMI),created onthe activities in2004,theseobjectiveswere takenoverbythe versity research oftheCRIV’s teams.Afterthetermination cooperationbetweendifferentgists andanimportant uni- human immunology, thetrainingofexperiencedimmunolo- the acquisitionofbasicknowledgeinvaccinologyand Vaccinologie (CRIV).ThemainpurposesoftheCRIVwere established theCentre deRecherche Interuniversitaire en the universityresearch inhumanimmunology. In1995,it In Wallonia, GSKBiologicalsplaysakeyrole indeveloping to come. and astrong stimulusforresearch inWallonia fortheyears worldwide. Itwillremain agloballeaderinbiotechnology serving thecommunitywithsolutionstoimprove health cal trials,GSKBiologicalswillleadthepackandcontinue € 50 millioninvestmentmadebyBaxter(80%) ) hasbeencreated in2004Crealys, toper- Baxter Healthcare Lilly DevelopmentCentre Aseptic is increasing its , 13 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page14 14 Biotech in Wallonia - Report 2005 EAT developed aseriesofhighqualitybiochipsproducts of thecapitalWallonia. core activitiesinthebusinessfieldofbiochipsheart AGhasnowdevelopedits group. Eppendorf Eppendorf ter forthearraysandrelated technologiesforthe Technologies ly intheNamurcompany, whichbecame placed itsconfidencedefinitive- In August2002,Eppendorf rays andnextgenerationmicroarray formats. advanced biochips,uniquelabelingmethodsformicroar- AAT combinestheabilitytodevelopand produce andacademicresearchers.supplier forpharmaceutical AATnology patentportfolio, becamealeadingbiochips andaninnovativetech- As aresult ofcombinedexpertise Wallonia Region. ofthe inhislabwith the support the research performed Technologies (AAT) in1999tocommercialize theresults of the UniversityofNamur, foundedAdvancedArray at ofCellBiologyandBiochemistry head oftheLaboratory To completetheexistingsupply, Professor J.Remacle, for biochips Eppendorf ArrayTechnologies asCompetenceCenter Technologies become leadersinthispromising field: “biochips”. Two companiesare positioningthemselvesto technology knownasDNAMicroArrays ormore simply inmicrochips tocreateof thelatestDNAchemistry anew One ofthehottopicsindiagnosticsisimplementation this fieldthankstocontinuousinnovativeresearch. nostics sector. Today, theregion remains attheforefront of ambitious program toboostthedevelopmentoftheirdiag- Since theearlyseventies,Wallonia hasembarkedonan TECHNOLOGIES AND BIOMEDICAL DIAGNOSTIC TOOLS P HOTO : Adipocytes precursors(LaboratoiredeBiologieCellulaire,UCL) (EAT) andisknownasthecompetence cen- (EAT) and Probiox . Eppendorf Array Eppendorf Array analytical tool available for determining atanyageone’sanalytical toolavailablefordetermining if theantioxidantdefensesare toolow, Probiox proposes an In order toknowifpeopleare becoming too“oxidized”and andhigh-classracehorse markets. sport, in thestudyandmeasurement ofoxidativestress inthe that naturalphenomenon:ageing.Probiox alsospecializes various diseases,degenerativeornot,inexorablylinkedto called oxidativestress, whichfavorsthedevelopmentof tems tipsinfavouroftheformer, there arisesacondition pro-oxidants andtheorganism’s antioxidant defensesys- When, inanorganism,thebalancebetweenlevelof research tools. development, production, anddistributionofarange Scientific Board; andEurogentec, aEuropean leaderinthe Professor LucMontagnier(Paris,France),whochairsthe ofoxidativestress; biology andinthebiochemistry recognised know-howinmolecular ing aninternationally Cellulaire etMoléculaire” oftheUniversityLiege,display- “Centre Suprafacultaire deRecherche enThérapie inthefieldofoxidativestress: the expertise complementary of fewactorsintentonpoolingtheiracknowledgedand of The birth Probiox -Oxidativestressprofiling nents. network andhasmore than1,600employeesonfourconti- AGhasaworldwidedistribution laboratories. Eppendorf basket ofresearch toolsforthebiotechnologyandresearch The EAT-developed products oftheEppendorf are part biochips inNamur. network. EAT issettingupfullproduction facilitiesfor globaldistribution while nowhavingaccesstoEppendorf's for quantitativeanalysisandagrowing product pipeline Probiox in 2001resulted from themeeting T505543int 17/10/0514:42Page15 and cost-savingtool. ing laboratorieswithamulti-functionsversatile,innovative provid- connection(TCP/IPport), viaanEthernet interface schedules andmanagesallthetaskscommandedby Thissystem be doubledbyanadditionalpipettingarm. chemistry, immunoassaysandcoagulation respectively, can The throughputs, 180,70and120testsperhourforbio- tests. immunoassays, andaclotdetectionmoduleforcoagulation distributionmoduleand aluminometerfor particles andlateximmunoassays, amagnetic clinical chemistry sal reaction cuvettesisequippedwithaphotometerfor whichaccommodatesdisposableuniver- The 3X3platform andcoagulation. says, clinicalchemistry away patentedautomatedanalyzer(3X3)forimmunoas- versatile bench-top,randomandcontinuousaccess,walk- Today, BiocodeHyceldevelopsreagents tofeeditsnew ofthe“Pegaseproject”.This hasresulted inthebirth ment ofanewrangenon-isotopicimmuno-diagnostics. chemiluminescent moleculestobeusedforthedevelop- University ofLiegeInstitutePharmacy, discovered new ofthe oftheChemicalAnalysisDepartment support On theotherhand,Biocode’s ownresearch team,withthe chemiluminescence technology. potential andautomationpathofitsnewsystembasedona Biocode Hycel reagents andinstruments.Through thisacquisition, say field,acquired Hycel,aFrench producer ofdiagnostic In 2000,Biocode,anestablishedplayerintheimmunoas- Biocode Hycel graphically asan“OxidativeStress Rosette”. lipids, DNA,orproteins. Alloftheseanalysesare presented sis ofiron metabolism;(iv)detectionofoxidativedamageto (iii)analy- measurements; (ii)traceelementdeterminations; file isbasedonfourtypesofanalysis:(i)antioxidantlevel oxidative stress status,onasimplebloodsample.Thepro- has significantlyimproved thedevelopment private investmentwithagroup ofinstitutionalinvestors. 2.25millionthrough a increase incapitalthe amountof research programs. Inaddition,Zentechsecured an Funds were needed,andtheDGTREonceagainsupported mune diseases. will openthedoortootherprojects aimedatcuringautoim- autoimmune antibodies.Thisfirstprogram totreat vasculitis immuno-absorption columnstocleansethebloodof Henogen, Zentechentered adevelopmentprogram of the needsofbiologylaboratories.Incollaborationwith New non-isotopicassaysare beingdevelopedtoaddress diagnostics andtherapy. munity enablesthefundingofresearch programs inboth ny isnamed andthenowwhollyBelgiancompa- from theItalianpartner for thecompany. First,amanagementbuy-outseparatedit Along withthenewmillennium,aerawasushered in its novelkitswere regular hitsonthediagnosticsmarket. research initskeydomainthereby remained apriorityand degree ofindependenceinmanagement.Investment The Belgiandivisionhasalwaysmanagedtomaintaina at thetimeofautomationwave. ininstrumentation exposure andvitalexpertise international thatbrought much-needed Radim, alargerItalianpartner The company’s growth wassecured bymergingwith has proven tobesuccessfulovertime. The continuousdedicationtoresearch inthisarea efforts had chosenthespecificnicheofautoimmunitydiagnostics. When Techland itsactivitiesintheearly1980s,it started Zentech ...Anewroadtothefuture located intheResearch Triangle Parkarea ofDurham,NC, tics anddiagnosticscompany. TheCompany´soffices are a spin-outfrom Tibotec-Virco, aBelgianHIV/AIDS therapeu- OncoMethylome Sciences OncoMethylome Sciences Zentech . Secondly, astrong focusonautoim- (OMS) wasfoundedin2002as 15 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page16 16 Biotech in Wallonia - Report 2005 In Vitro and economical.Allkitshavereceived theCEmarkingfor sticks. Theyare quick,simpletouse,sensitive,specific, matographic techniqueandusecoatednitrocellulose Tests immunochro- are basedonthecolloidalgoldparticle pathogens. detect humanentericandrespiratory tic kitsbasedontheimmunochromatographic methodto Coris BioConcept Coris BioConcept gy overothertechnologiesinleadingmedicaljournals. repeatedly expressed theadvantagesofMSPtechnolo- tic applications.Thescientificoncologycommunityhas achieves excellentspecificityandsensitivityinitsdiagnos- readily availablesamples(suchasurineandblood) effective fordetectingcancerearly,the technologyvery in cells.Thischaracteristicmakes on abackground ofnormal and iscapableofdetectingafewhyper-methylated cells onstandard labequipmentformass-screening performed nology fordetectingmethylatedgenes.Thedetectionis the earlydevelopmentofallcancers.OMSappliestech- Aberrant hyper-methylation ofgenesplaysacentralrole in Hopkins Universityandisexclusivelyin-licensedbyOMS. thatwasdevelopedatJohns ic PCR)technologyplatform tion genemarkersandtheproven MSP(methylation-specif- The company’s activitiesare basedonvalidatedmethyla- early detectionandindividualizedtreatment ofcancer. OMS isspecializedinmolecularoncologydiagnosticsfor USA, inWallonia, andintheNetherlands. Diagnostics. develops, produces andsellsdiagnos- years, Molecular Biology, foundedthecompany. Inacoupleof Renard, of from theUniversityofLiegeLaboratory andDr. in1985whenProf. J.Martial starts The story A. Eurogentec BIOLOGICALS PRODUCTION IN RESEARCH AND office inSwitzerland. France, Germany, theUK,Netherlands,andabranch grown intoa279-employeecompanywithsubsidiariesin EGT, intheLiegeSciencePark,has withitsheadquarters in thefieldofoligonucleotidesynthesis. taiel3Dskin culture modeling DNA-microchips Straticell Probiox Molecularbiologydiagnostics Sciences Affinity supports Molecularoncologydiagnostics OncoMethylome Diagenode Affiland Di Created since2000 Diagnosticsforenvironment andfood Zentech Diagnosticsreagents Unisensor reagents Diagnostics Gamma Technologies DNA-microchips Diagnosticsreagents Array Eppendorf D-Tek Diagam Research anddiagnosticsreagents Diagnosticsreagents Coris BioConcept Reagentsandinstrumentation DiBiosource Biocode Hycel Analis Created before2000 Companies indiagnosticsandmedicaltechnologies Table 7 Eurogentec (EGT) emergedasaworldwideleader contamination agnostics reagents andspecialtherapy agnostics reagents andinstrumentation T505543int 17/10/0514:42Page17 offers oligonucleotidesynthesis withalargerangeofmodifi- ❚ nized around twobusinessunits: activitiesofenabling technologiesare orga- The platform products.distribution ofthird-party Contract ManufacturingOrganisation(CMO)activityandthe ❚ America. ofEGTNorth in SanDiego(CA,USA)thatisnowpart and theacquisitionofanoligonucleotideproduction facility withResearchthrough BiolabsinSingapore apartnership geographic expansionofEurogentec continuedin2003 Americanoffice. The another strategicstepopeningaNorth EGT jointventure inJapan.InMay2002,Eurogentec took Indeed inAugust2001,thecompanyestablishedNippon ❚ ambitious expansionprogram: capital of Because ofthisstrong balancesheetandanincrease of in 2003/2004. Revenues grew from petitive environment ofgenomicsandproteomics suppliers. EGT remained consistentlyprofitable intheextremely com- Under theleadershipofJ-P. thecompany’s Delwart, CEO, The “Tools forGenomicsandProteomics” department toexpandtheR&D program, the Invest internally growth willcomefromExternal expansionofterritory. € 5 million,Eurogentec cannowpushforward its € 12.3 millionin1998to € 33.3 million P trials orformarketsupply. GMP lotsofrecombinant protein orplasmidDNAforhuman production process designtotheactualmanufacturingof ceuticals. Projects canbetakenfrom theearlieststageof purification andfull-scaleGMPproduction ofbiopharma- downstream gene cloningandsynthesis,fermentation, The companyoffers acompleterangeofservicesincluding batch manufacturing. development andproduction servicesforcGMPclinical Manufacturing Organization(CMO)deliveringresearch, ❚ ProteinArrays are alsoamongitsexpertise. range ofanimalmodelsaswellpeptide,antibodyand bioactive peptidepurposes.Antibodyproduction inawide the designofpeptides,eitherforantibodyproduction or range ofkitsandconsumables.Italsogathersknow-howin Time PCRproducts, DNAMicroArray servicesandawide cations, oligonucleotidesforInVitro Diagnostic(IVD),Real- development project onsmall therapeutic peptides.Afew In theearly80’s, someUCBscientistslaunchedaninitial use. and peptido-mimeticsforpharmaceutical tical company, isspecializedincustompeptide synthesis UCB Bioproducts UCB Bioproducts HOTO EGT’s “Biologics”unitisafull-serviceContract : ß-lactamase molecularmodeling(Centred’IngéniériedesProtéines, Ulg) , adivisionofUCBGroup, apharmaceu- 17 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page18 18 Biotech in Wallonia - Report 2005 peptide forcommercial newChemical Entitiesdrugs. peptidesandcurrentlypharmaceutical majoritysupplierof UCB Bioproducts divisionisleaderinthefieldofindustrial around 300employeesinBelgium,USandJapan,the With 2004revenues upmore than20%since2003and Chemical Entitiesdrugs. cial. Thiscontributedtocommercialisation of3new stages ofclinicaldevelopmentfrom preclinical tocommer- customersinalargenumber ofprojects invarious support Those lastyearshaveseenUCBBioproducts successfully vices isavailable. als andproduct registration, acomprehensive setofser- ucts. From research toproduction, clinicaltri- topreliminary italsooffers innovativeprod-ties touniversitydepartments, registration. research Thankstoits internal anditsclose ingredient peptideactivepharmaceutical for supporting FDA-approved facilitiesanditsstrong expertise regulatory tions toitscustomersthrough alargecapacityinitsGMP, UCB Bioproducts canprovide acompleterangeofsolu- peptide synthesisyearafteryear. Bioproducts becametheleaderinfieldofindustrial atasteadypace,UCB trial purposes.Buildingitsexpertise from thefirstproject toproduce custompeptidesforindus- byimproving andexploitingtechnologyissued It started P created: UCBBioproducts. research know-howofthe UCB Group, anewcompanywas the Wallonia and Region,andwiththeindustrialexpertise new endeavour. from In1981,withsomefinancialsupport simply dumped;onthecontrary, ofa itbecamethestart amount ofknowledgeacquired duringtheprocess wasnot apeutic interest andtheproject wasstopped.However, the months laterthecompoundswere foundtobeoflittlether- HOTO : Chromosomes ("GênesetEthique"Pass ©BeneluxPress) (clarification, detoxification). metics andpersonalcare (antimicrobials), wineindustry painrelief,(cholesterol weightloss),cos- lowering,arthritis cal aids,woundcare, tissueengineering),nutraceutics andmedicaldevices(surgi- inpharmaceutical particularly KitoZyme’s players,more products applytoglobalindustry cose. sugar units:glucosamine,N-acetylglucosamineandglu- and quality. Theproduct rangeisbasedoncombinationsof are characterizedbyconstanthighpurity, specifications from trulyrenewable fungalresources. Thesebiopolymers KitoZyme KitoZyme ing pointin2005. ity andcapabilityinvestmentovertheyearswithculminat- bysignificantcapac- All thoseachievementsare supported is manufacturinguniquegoodvaluebiopolymers T505543int 17/10/0514:42Page19 P HOTO : 1/ Somatic embryos colony (Observatoire du MondedesPlantes,Ulg) colony(Observatoire 1/ Somaticembryos 3/ Atomisor(CWBI,Ulg-FSAGx-Photo Houet) 2/ GlaxoSmithKlineBiologicals 19 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page20 20 Biotech in Wallonia - Report 2005 ceuticals arrivingonthemarket. required tomanufacture the hundreds ofnewbiopharma- “Contract manufacturing”extendstheproduction capacity generated bygenomicsandproteomics. tational powertohandleandanalyzetheconsiderabledata bringnewsoftware andadditionalcompu- “Bioinformatics” forth. functionalgenomics,andso teomics, pharmacogenomics, exploiting specifictechnologies,namely, genomics,pro- services”helpdiscovernewagentsby “Drug discovery ating newsub-sectors: considered non-core totheformer. arisecre- Opportunities the dooropentonewcomerscontinueexploitwhatis selectively andtofocusoncore competencies.Thisleaves tochoosetheirstrategiesmoregathered enoughexpertise and explore newtechnicalfields.Nowadays,theyhave early days,companieshadtofollowvariousresearch paths isgrowing atasteadypace.Inthe The lifescienceindustry PROVIDERS SERVICE ANDTECHNOLOGY 2 2 isrsBioinformatics Biosiris Created before2000 yxErp Phagedisplay baseddrugs Bioinformatics cloningandDNAengineering Molecular Dyax Europe Genetics Delphi Contractservices Bioinformatics BioXpr BioPharma Arlenda Bioinformatics Created since2000 peptides Pharmaceutical UCB Bioproducts Telemis Bioinformatics Contractresearch andproduction Contractresearch andproduction Quality Assistance Lambda-Plus Specialty chemicals Henogen Ligandsandnewdrugsinteractedwith Floridienne Contractresearch andproduction Euroscreen Eurogentec Service andtechnologyproviders Service Table 8 membrane receptors T505543int 17/10/0514:42Page21 covery, developmentandcommercialization ofantibodies, companyfocusedonthedis- Dyax isabiopharmaceutical Dyax Europe mals. ing abetterapproach fortheconstructiontransgenicani- Delphi Geneticsintendstodevelopnewvectortoolsallow- els; thisresearch program hasreceived the“Eureka” label. animalmod- aimed atacceleratingthedesignoflaboratory The companyisalsoinvolvedinaresearch consortium new approaches inDNAengineering. laboration withothercompaniesforthedevelopmentof Delphi Geneticshasalsobuiltupanetworkofresearch col- dote genes. the useofuniquetechnologiesusingbacterialpoison-anti- The products developedbyDelphiGeneticsare basedon in AsiaandEurogentec inEurope. using Express” kits,increases theyieldofprotein production field ofDNAengineering.Itsfirstproduct line,the“Staby in November2001,developsservicesandproducts inthe Delphi Genetics Delphi Genetics SERVICES DRUG DISCOVERY E. coli . Theseproducts are distributedbyTakara-Bio , aUniversityofBrusselsspin-off founded chase fortheirownGPCRresearch programs, whilethe research customerspur- toolswhichbiopharmaceutical create abusinesssellingGPCR products, servicesand Founded in1994,Euroscreen applieditsGPCRscienceto GPCR ligandsorblockthebindingofligands. companies todayare either development atpharmaceutical prising thenthataboutathird ofthedrugsinuseor Itisperhapsnotsur- ands ofGPCRsonourcellsurfaces. our cellsare transmittedthrough thebindingofspecificlig- within thecell.Infact,about90%ofallsignalsreceived by nals (ligands)whichwillthenactivateanexactfunction ofeachhumancellandwaitforspecificsig- on thesurface G-protein coupledreceptors (GPCRs).Different GPCRsare Euroscreen Euroscreen is beingstudiedforcysticfibrosis. bypass),whileDX-890 angioedema andcardiopulmonary trials. DX-88isbeingstudiedintwoindications(hereditary currently hastworecombinant proteins inphaseIIclinical pounds thatcanbeusedastherapeutics.Thecompany a broad rangeofsmallprotein, peptide,andantibodycom- Dyax usesapatentedphagedisplaytechnologytoidentify inLiege,knownas subsidiary located inCambridge,USA,andoperatesitsEuropean the areas ofinflammationandoncology. Thecompanyis in medical needsthathavenotyetbeenmet,particularly small proteins andpeptidesastherapeuticproducts for P HOTO : unnhmlaeeas(UnitédeMicrobiologie,UCL) Cunninghamella elegans is specializedinanarea ofbiologyknownas Dyax Europe . 21 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page22 22 Biotech in Wallonia - Report 2005 nological andfoodcompanies indevelopingresearch cosmetic,biotech- aims tocollaboratewithpharmaceutical, molecular modelingofbiologicalmolecules.Thecompany Biosiris in thisfield. well asinNamurandLouvain-la-Neuve,playaleadingrole University labs,especiallythoseinLiegeandGembloux, as providing adequatesolutions. aimatanalyzingthis massofnewdataand Bioinformatics 18months.Software isanothermatter… every performance ue togrow according toMoore’s law, doublingspeedand sophisticated software. Computersandprocessors contin- can onlybeexploitedwiththefastestcomputersandmost of biotechnews.Themassiveamountdatanowavailable in early2001,genomicsandproteomics are attheforefront With thepublicationoffirstcompletegenomesequence BIOINFORMATICS diabetes. several purinergicreceptors andSHIP2foruseintypeII for Euroscreen’s includeORL1/nociceptin, licensingefforts access tothisintellectualproperty. Otherpatentedtargets will beenteringintolicenseagreements withEuroscreen for CCR5 receptor asatargetsuchHIVdrugdevelopmentand in thetreatment ofAIDS.Severalcompaniesare usingthe of HIVvirusintohumancellsasanewtherapeuticmodality useinblockingtheentry and antibodies,fortheimportant such patents,Euroscreen hasrightstotheCCR5receptor Among 15 years,resulting inasubstantialpatentportfolio. the 230currently characterizedhumanGPCRsoverthelast Brussels, haveclonedandcharacterizedmore than20of Euroscreen anditsacademicpartner, Universityof oncology. of drugcandidatesinthefieldsneuroscience and collaboration withCephalonInc.fortherapididentification plus technologytransferandarecent drugdevelopment ofnewGPCRtargets ships withSolvayforthediscovery company’s capabilitieshavealready resulted inpartner- companies.Indeed,the grams withbiopharmaceutical now allowEuroscreen itsdrugdevelopmentpro- topartner services are usedtopursueitsdrugtargetprograms which of itsown.Theprofits from thesalesofproducts and company alsoestablishedanewdrugdevelopmentgroup develops activitiesinthefieldofsimulationand validates andcommercializes an integratedsuiteofindus- analysesandstatistics. Themissioncompanydevelops, ry of Liegebyaninter-disciplinary inlaborato- teamof experts Arlenda tion algorithms. ranked intheworld’s topthree forprotein structure predic- applied tolifesciences,andin2002,itsalgorithmswere BioXpr offers fifteenyearsofexperienceinbioinformatics teomics orgenomicsdata,andsoon. ate intelligentdatabasestoenhancedata,process pro- advanced andprogressive software tospeedupR&D,cre- the lifesciencessector. Thecompanycandesign appliedtoR&Din products inthefieldofbioinformatics, BioXpr various fieldsincludingmedicineandpharmacy. These “high-tech”products findspecificapplicationsin core competencies:transmission,imageandsecurity. active inmultimediatechnologicalsolutionsbasedonthree Telemis PC orascanningtechnology. a conventionalpaperapproach: EDCusingPC,PDA/tablet ize thedatacollectionprocess usuallycarriedoutthrough Lambda-Plus offers awiderangeofsolutionstocomputer- client’svices tomeeteachandevery specificneeds. technological solutionsassociatedwithcustomizedser- Electronic DataCapture (EDC)solutionsandinnovative computing skillsplusabackground inCRO,avastsetof incutting-edge to provide worldwideservicesofexpertise Lambda-Plus (Bepitopes). genic properties developed anefficient methodfortheprediction ofanti- In additiontothesecustomizedservices,Biosirisalso of apeptide/protein inabiologicalmembrane,andsoforth. improve orprevent protein interactions,modifytheinsertion improve stability, peptides, generatecomplementary several different proteins andtosuggestmutations relationships. allowedBiosiristoworkwith Thisexpertise branes withrespect totheirsequence-structure-activity Its specificitiesare thestudyofproteins, drugsandmem- research trends. mechanisms ofbiologicalsystemsandselectinnovative er newtherapeuticmolecules,understandtheworking Biosirishelpsindustrialgroups discov- members' expertise, andits activities. Through itsin-housetechnologyplatform , aUniversityofNamurspin-off, offers servicesand is aspin-off oftheUniversityLouvainandis was created in2003asaspin-off oftheUniversity is one of the very fewEuropean companies is oneofthevery T505543int 17/10/0514:42Page23 nant solublehumantissuefactor fortissueandbonerepair Henogen hasalsodeveloped anewmolecule,therecombi- opment isongoing. tion ofpost-transplantationlymphomas;theclinicaldevel- the EEClabeledthisvaccine"orphandrugs"forpreven- present indifferent oflymphomas. InOctober2002, forms virus, whichisresponsible formononucleosisandisoften II clinicaltrialforanewvaccineagainsttheEpstein-Barr In mid2004,thecompanysuccessfullycompletedaphase proteins ingeneral. human vaccineandgenetherapyfields,recombinant and bioengineering,Henogencanspeedupprojects in inpreventiveBenefiting from medicine yearsofexpertise 1.5 milliontocreate thecompanyearly2000. and theUniversityofBrusselsraisedinitialcapital With thehelpofaventure capitalfund,GSKBiologicals Henogen relationship withGSKBiologicals thatleadtothecreation of prises. Professor A.Bollen’s hasalongstanding laboratory enter- soilforstart-up University ofBrusselsoffers afertile ers mostofthebiotechnologyresearch activitiesofthe The creation inGosseliesofa“biotechnopole”whichgath- University ofBrussels Henogen: A5years-oldmaturespin-offofthe CONTRACT MANUFACTURING dures, from theearlyoptimizationtoitsroutine use. trial solutionsdedicatedtoallphasesofanalyticalproce- P HOTO : GlaxoSmithKline Biologicals . € batch manufacturing(seealsopage16). development andproduction servicesforcGMPclinical Manufacturing Organisation(CMO)deliveringresearch, Eurogentec’s “Biologics”unit,isafull-serviceContract Out ofthetwoEurogentec’s businessunits,called Eurogentec of ImmunoToko. plantation area, demonstratedbythelate2004acquisition products inthetrans- ing itsownlineofbiopharmaceuticals tackle newchallengesinthefuture, focusingonestablish- With ateamofmore than80scientists,Henogenisready to Immutep showthecompany’s broad scopeofactivities. Biologicals, PasteurInstituteofParis,Stallergenesand inBelgium.Current withGSK Pharmacy partnerships which havebeenvalidatedbytheGeneralInspectionof to production ofbatchesforclinicaltrialsinGMPfacilities, Henogen’s servicesrangefrom theearlystagesinresearch product are ongoingsincemi-2004. accomplished. Clinicalstrialsofthisnewpharmaceutical safety inpre-clinical modelshavebeensuccessfully tion underGMPconstraintsandthedemonstrationofits as wellforsurgicalglue.Thedevelopment,theproduc- 23 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page24 24 Biotech in Wallonia - Report 2005 industry. to becomeaprovider ofantibodies andbiologicalsforthe Moreover, enablestheCER thisclose-to-the-fieldexpertise vices andtop-classdiseasedetectiondiagnostics. ser- ter helpstheagriculturalcommunitieswithveterinary the “Centre d’EconomieRurale”(CER)inMarloie.Thiscen- cial authoritiesalsopromote biotechnologyresearch with ogy tomovefrom research labstothemarket.Theprovin- enablestechnol- ed. Closecommunicationwiththeindustry versity centerswhere topresearch programs are conduct- Gembloux, LiegeandLouvain-la-Neuveare renowned uni- tural andforest sciences. from it.Thishelpstobooststronglearn research inagricul- andforests. Thepeopleliveclosetonaturefarmland and Occupying 55%oftheBelgianterritory, Wallonia isrichin quality, intheirmilk. aswelltoproduce pharmaceuticals genetically selectedandbred toprovide improved meat improved resistance todeadlydiseases.Cattlecanbe extreme climaticconditions.Modifiedanimalsshow increased resistance toinsectsoracapacitysustain duce therapeuticproteins. Transformed seedsfeature an and cholesterol-free nutriments.Newtransgenicplantspro- crops. Thisenablestheproduction ofnon-allergenicfoods of newplantspeciesandtheimprovement ofexisting nology introduces geneticengineeringforthedevelopment ofthefoodindustry. part sent animportant biotech- Modern microorganisms. These“traditionalbiotech”products repre- bread by andwine,whichallbenefitfrom fermentation products. Famousexamplesincludebeer, cheese,yogurt, naturalrawmaterialintofoodandotherfinished transform For centuries,biologicalprocesses havebeenusedto AGRI-FOOD 2 3 Galactic and rationalizeconventionalbreeding. cular markers,andmarkerassistedselectiontoaccelerate ferent biotechnologymethodssuchasculture invivo,mole- and breeding ofindustrialchicory. Thegroup developsdif- Cosucra Groupe Warcoing isalsoinvolvedintheresearch inuline. process forchicory and transformation universities, itwasabletodevelopanefficient extraction Thanks toitsownresearch anditstightcontactswiththe fortheproduction ofsugarandfibres.industrial chicory Cosucra GroupeWarcoing toInuline Cosucra groupWarcoing: FromChicory lactic acidandlactates. time,worldleaders intheproduction of become, inashort toGalactic.Thishelped thecompanyto cial support As amajorityshareholder, Finasucre provides strong finan- new substancesandadditivesforthefoodindustry. gy. Severalcompaniesplayanactiverole indeveloping Other naturalsubstancesare alsoexploitedbybiotechnolo- proof thatbiotechnologycanbehelpfultotheenvironment. the future successofthecompany. Galacticisaliving andwillensuretic acidspotentialofgrowth isenormous thelac- industries offood,cosmeticsandpharmaceuticals, plastics. Withthousandsofpossibleapplicationsinthe (PLA), whichisapromising, substitutetotraditionalthermo- developed abiodegradablepolymer, thePolyLacticAcid nature-friendly processes. Forexample,thecompanyhas duce higherqualitylacticacidsfrom pure sugarwith Galactic for itsexploitation. anddevelopedgenuineindustrialprocesses their expertise hastakenadvantageof yield improvement. Theindustry advanced research indevelopmentofplantqualityand Local universitylaboratoriesare renowned fortheir are widelycultivatedintheregion.Sugarbeat andchicory develops originaltechniquestoexploitandpro- is apioneerinexploiting T505543int 17/10/05 14:42 Page 25

Beldem: Leader in food ingredients technology Progenus Beldem (Andenne) is a leading growing company in food Based on a technology platform of DNA and genetic infor- ingredients. It produces enzymes that are mainly used in mation analysis, Progenus is a company which today pro- baking and milling sectors but additional growth comes poses solutions to breeders, retail chains, meat processors from products for animal feed. Beldem produces also on and consumers in need of a reliable system to ensure ani- the same site baker’s yeast and yeast extracts in a recently mal selection, animal and species identification and meat built production facility. In Saint-Vith, Beldem produces dry products authenticity. By using DNA tests in animal breed- and liquid sourdoughs for bread quality improvement. ers, a Gene Marker Profile program is carried out in order to select the best animals to improve milk or meat quality and quantity. Likewise, species identification of meat prod- Biopole: Specialist in enzyme purification ucts or animal identification from the farm to the consumer Another active player in enzyme technology is Biopole, is important for economic, religious and public health rea- which develops and commercialises innovative products sons. Progenus has developed specific genomic DNA based on its expertise in human and animal secretory mol- probes that distinguish between DNA samples of most ecules. Biopole was the first company to implement the use species such as pigs, horses, sheep, cattle or fish. of lactoperoxydase and lactoferrin in nutraceuticals, animal feed, oral healthcare and cosmetics products. Future devel- Phytesia opment will enable Biopole to enter the industrial food Phytesia, a University of Liege spin-off, specializes in the enzymes production, specially the industrial enzymes purifi- production of high added value plants. The company cation by HPLC at industrial scale. develops and markets new micropropagation products for horticulture, floriculture, agriculture, forestry, conservation and industrial applications. Belovo: Egg Science & Technology Belovo was the first company in Belgium to benefit from Phytesia has perfected techniques for germination and in regional financial support in the biotech sector. In 1980, the vitro cultivation, acclimatization and large-scale production SRIW’s support helped Belovo grow into a multinational of hardy orchids from Europe, North America and other company led by originality and high technology. Belovo has temperate countries. acquired a solid international reputation for its range of highly functional egg products, including egg powders, refined egg ingredients (Lysozyme, Avidin, Lecithin) and DNAVision low cholesterol shell eggs (Columbus). The research and development company DNAVision pro- The company continues to invest in R&D programs in egg vides expertise in molecular biology, especially in the field science and technology. Working in a GMP environment, of genetic analysis. With state-of-the-art instrumentation the company is able to meet the strict requirements of the and methods validated in a quality environment, the com- food and pharmaceutical industries throughout the world. pany provides analytical services designed for the health Among major successes recorded by the company are the and agro-alimentary industries. launches of pharmaceutical grade lysozyme, infant food grade egg yolk lecithin and Columbus egg and foods. DNAVision, founded in May 2004, already provides various application notes emerging from scientific expertise acquired mainly in the laboratories of the University of Brussels in the field of characterisation of genetic polymor- PHOTO: 1/ CRA-Gembloux (photo Marc Deckers) - phic markers. 2/ In vitro callus proliferation (Observatoire du Monde des Plantes, Ulg) T505543int 17/10/0514:42Page26 26 Biotech in Wallonia - Report 2005 iiai Biologicalcontrol products Animalselection Foodanalysisandcosmetics breeding Plant chitosanesderivedingredients Biopharmaceuticals Viridaxis Foodanalysis Quality Partner Progenus Lacticbacteriaandderivates Phytesia KitoZyme products Diagnostics forfoodcontamination DNAVision Lacticacidandderivates Biologicalcontrol products Created since2000 UCB Bioproducts Enzymes THT Enzymes Horpi Systems Galactic Enzymes breeding Plant Enzyme &Derivates Eggandeggderivates Enzybel Plantengineering Enzymepurificationandrefining services Cosucra Groupe Warcoing Foodadditivesandenzymes Bioplant inVitro Environmental additives Biopole Microbacteria andculture media Biochem Europe Belovo Beldem Avecon Artechno Created before2000 Companies inAgricultureandFood Table 9 P HOTO : CRA-Gembloux (photoMarcDeckers) T505543int 17/10/0514:42Page27 ENVIRONMENT the companyconductsseveral ambitiousresearch pro- representR&D efforts and more than10%oftheirturnover biotechnology forcleaningandwaterpurification.Their Neuve. Byusingenzymesandbacteria,Realcouses Founded in1968, Realco use ofbioremediation torecycle specificpollutants. fungi with26,000species.Thisledtothedevelopmentand worldcollectionof of theUniversityLouvain,fourth ofMycology companies canusetheservicesofLibrary bring outinnovativeservices.Morever universitiesand universities andcompaniestopooltheirinterests andto DGTRE, through itsfocusedfundingprograms, hashelped friendly” research from programs. the Dedicatedsupport Therefore specificresearch conduct“Earth- departments helping toimprove well-beingandkeeptheregion “clean”. Each universityinWallonia wouldliketoplayitsrole in 1billionperyear. reach metal contaminationofgroundwater hasbeenestimatedto the worldwidemarketforbioremediation oforganicsand ent typesofpollutants.Thisismore thanwishfulthinkingas restore soiltoitsprevious state ortocleansewaterofdiffer- Bioremediation, forexample,usesmicroorganisms to ment. to restore andeventuallyimprove thequalityofenviron- bacteriaandfungi, the useofmicroorganisms, inparticular Indeed, “Environmental Biotechnology”canbedefinedas noble goal. sible. Biotechnologycanhelpreach thisambitiousand haps evenrestored toits“natural”conditionwherever pos- Our planetdeservestobeprotected from pollutionorper- Realco is nowbasedinLouvain-la- 2 4 Biorem duction in fermentor vessels,...Thereforeduction infermentor Agrostar can development ofspecificbreakdowns totheindustrialpro- research tothesetupofpracticalmethodsusefrom the atrulyintegrated servicefrom applied industrial partners Inthisway,starters. Agrostar offers its customersand microorganisms forenvironmental use,knownasbiological For thepasttwentyyears, Agrostar and allowscontinuoussupervisionofthework. avoid manyhumaninterventionsonthetreatment location, for thetypeofpollutant.Aremote monitoringprocess can subsoil microorganisms thathavebeenpurposelydesigned are abletoinoculatehomogeneouslyinthesoiland ing factorsinabioremediation process. Thetreatment units equipment, andbringinganefficient solutiontotheinhibit- ized, preventing allkindofincompatibilityproblems ofthe The different stepsofabiologicaltreatment are rational- ation technology. treatment inoneuniqueunit,addedtoaproper bioremedi- ering ofallthedifferent functionsinvolvedinthesanitation carbons. TheconceptofBiorem isconsistingonthegath- soils andaquiferscontaminatedbyvariousrangeofhydro- Biorem waste water. using enzymesasearlypossibleinthepurificationof of has ledtoapatentthatdemonstratestheimportance grams withuniversitiesofLouvain,BrusselsandLiege.This is acompanyengagedinthein-situtreatment of Agrostar has beenproducing 27 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page28 28 Biotech in Wallonia - Report 2005 sented inthetable10. inthisfieldareThe companiesoffering pre- theirexpertise with atotalbudgetupto in10countries coordinates of26partners theR&Defforts (www.sophied.net).and dyingindustry Thishugeproject with theintroduction ofindustrialbiotechnologiesinthedye project oftheEuropean sixthframeworkproject dealing Wetlands Engineering istheSMEleaderofanintegrated device, andindustrialaeratedcompostingtechnology. mentor, wastewatertreatment unit,research compostpilot processes: innovativesensorsforbiotech,equippedfer- pany produces hardware andsoftware systemsforbio- (dyes, colored wastewater,...). Complementarily, thecom- (laccases) forbioremediation ofaromatic compounds develops theproduction offungalbiomasandenzymes Wetlands Engineering Wetlands Engineering expect. arewho distributeorprescribe entitledto biologicalstarters whichallthose thescientificandtechnicalsupport provide elnsEgneigWaste treatment Waste managementsolutions Wetlands Engineering Waste management Created since2000 Bioremediation enzymes starter Biological Realco EcoTerres Biorem Agrostar Created before2000 Companies activeintheenvironmentbiotechfield Table 10 , afastgrowing innovativestart-up, € 10 million. T505543int 17/10/0514:42Page29 P HOTO : 4/ Auxine induced tomato root (Observatoire duMondedesPlantes,Ulg) 4/ Auxineinducedtomatoroot(Observatoire 3/ Rhodotron TT200 (IonBeamApplications) 3/ RhodotronTT200 2/ Lyophilisator (CWBI,Ulg-FSAGx-PhotoHouet) 1/ LaboratoiredeBiochimieetBiologieCellulaire,FUNDP 29 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page30 3 30 Biotech in Wallonia - Report 2005 AND SUCCESS A REGIONFORGROWTH WALLONIA: P HOTO : IBMM, ULB T505543int 17/10/05 14:42 Page 31 31

EXCELLENCE IN RESEARCH: THE BIOTECHNOPOLES

Tableau 11 Students registered in Universities in 2003 (*) If financial analysts were to rate Wallonia on the basis of 1 2 Fundamentals and Technical Analysis (TA), they would UCL ULg ULB FUNDP FUSAGx UMH Others Total certainly refer to the region as a “Strong Buy”! Science 3 3,605 3,132 3,457 1,158 999 547 1,057 13,955

Fundamentals imply “Excellence” found in people and Medical 4,801 4,450 3,565 967 - 223 - 14,006 sciences 4 infrastructure, whereas TA looks for strong support and “Excellence in Incentives”. Total 8,406 7,582 7,022 2,125 999 770 1,057 27,961

Aware of the importance of knowledge-based innovation, (*) abbreviations are explained in the table at the end of the brochure the Wallonia Region has always promoted high quality 1 Including FUL (Fondation Universitaire Luxembourgeoise) 2 Others include FPMs, FUSL and FUCaM education. Indeed, it actually finances and hosts nine 3 Applied sciences, agricultural sciences and plant engineering 4 Medicine, dental & veterinary sciences, pharmacy and physical training sciences university centers and scores of research institutes that produce hundreds of science graduates. Source: Cref2004

The breakdown of students registered in major Universities in 2003, in life and medical sciences, is Tableau 12 given in Table 11. Science and Technology Parks containing most of the biotech companies in Wallonia

This high concentration of “brains” constitutes a reservoir Location Name of talented and well-educated scientists. Science Parks Biotechnology is among the fastest growing fields and Gembloux/Namur Crealys Science Park expertise ranges from plant engineering to the latest genomics and proteomics technologies. Gosselies/Charleroi Aéropole

Liège Liège Science Park A strong will of academics to increase the value of research led to nurturing “excellence” in relations with Louvain-La-Neuve/ Louvain-La-Neuve Science Park the industry. Ottignies-LLN This further stimulates the companies that are the Mons Initialis Science Park region’s driving force: GSK Biologicals, UCB

Bioproducts, Eurogentec, Baxter Healthcare, Eli Lilly, Technology Parks Cosucra, Beldem, Belovo and many others are paving Seneffe Seneffe Technology Park the way to success. Ghislenghien Business Park Qualitis T505543int 17/10/0514:42Page32 32 Biotech in Wallonia - Report 2005 cies. Thisproject iscombining thescientificleadingedge academic research byusingthe synergiesofcompeten- They willprovide aworldleadingservicetocompaniesand allowing multipleacademiccore facilitiestoco-operate. environment laboratory main objectiveistobuildavirtual the launchofINTERREGIIIALMA-GRIDproject. Its continuity oftheGIGAproject, 2005hasbeentheyearof period thatamountsto European authorities,withatotalbudgetforthe2003-2006 by local,WalloniaGIGA isfinanciallysupported and ical companies. acts asahingebetweenuniversityresearch andbiomed- in theexpandingfieldoffunctionalgenoproteomics, GIGA andknow-how Through itswiderangeofskilledexpertise ing educationforcareer development. ❚ ❚ protein production; transcriptomics, transgenics(mouseandzebrafish), ❚ es ofcancerandinflammation; scientists oftheULgfocusingongenoproteomic approach- research(CBIG): amultidisciplinary centercounting280 ❚ a uniquestructure composedof4axes: Located withinabuildingoftheUniversityHospital,GIGAis Génoprotéomique Appliquée”). The firstexampleis ation betweendifferent facultiesanddepartments. the ULghasimplementedapolicyof“crossborder” cooper- Understanding thatinnovationcancomefrom alldirections, tion regarding bothcollaborationswithindustries. The The PoleofLiege excellence inbiotechnology:the“biotechnopoles”. companies hascontributedtothecreation ofcenters The highconcentrationofuniversitiesandlargehealthcare “Valley” stretching from thewesttoeastofWallonia. along and businessparksfrom MonstoLiegeform rest oftheworld.Thecreation and extensionofscience positioned toaddress neighbouringmarketsaswellthe Located inthecentre Europe, ofWestern Wallonia isideally A trainingcenterinbiotechnologydedicatedtocontinu- Laboratories andoffices forbiomedicalbusinesses; genomics,proteomics,Core facilitiesinbioinformatics, The Centre ofBiomedicalIntegrativeGenoproteomics University ofLiege GIGA € (ULg) hasalongandstrong tradi- 56 million. Furthermore, inthe 56 million.Furthermore, (“Groupe Interdisciplinaire de created inNovember2003. emphasis onthewatermanagementthrough the Besides, theUniversityofLiegehasalsoputastrong environmentextremely around supportive theULg. in Walloon biotechnologyandnumerous spin-offs offer an the the Traces), the among whichthe ing, knowledgeandbusinessinvariousresearch centers, The Diepenbeek). (University ofMaastricht),CenStatCentre (LUC Institute (RWTH Aachen),GenomeCentre Maastricht GIGA (UniversityofLiege),MolecularBiotechnology GenomeCenters: competencies ofthefourparticipating The Industries). CRGB Indeed, anumberofspin-off companies havealready been of newtestsevaluatingvaccine efficiency andsecurity. cine strategiesapplicabletotheneonate,development autoimmune diseasesandallergies,definitionofnewvac- new immunotherapystrategiesfortransplantrejection, Region, theIMIisactiveinseveralfields:developmentof ofWalloniaBrussels andGSKBiologicals,withthesupport betweentheUniversityof ofaninnovativepartnership Born ates inmanyfieldsofbiotechnology. fame,andoper- tute enjoysahighdegree ofinternational dedicated toteachingandacademicresearch. Thisinsti- Established atCharleroi since1999,theIBMMismainly Institute ofMedicalImmunology Institute ofMolecularBiologyandMedicine biopole thebestofitslifescienceresearch activity: The financial commitmentsandisdrivenbyacommonvision. byacademic,Walloniahas beensupported andEuropean “Biopole ULBCharleroi”. Auniquestructure inWallonia, it Charleroi bringsittogetheratitsbiotechnologypoleor From basicresearch toeconomicvalue,theAeropole The PoleofGosselies(Charleroi) CIP CRPP University ofLiege BioLiege University ofBrussels (Research CenterfortheManagementofBio- (Centre forProtein EngineeringUniversity)andthe (Centre deRecherche surlesProtéines Prion), CEIB association, playingacentralnetworkingrole CART (Interfacultary Centre ofBiomaterials), (Interfacultary (Centre forAnalysisofResiduesin (ULg) hasmergedtheory, learn- (ULB) hasconcentratedinthe (IMI). (IBMM) and Aquapole T505543int 17/10/0514:42Page33 1,000 students,itisoneofthe largestcentersofexcellence utation attractsmore than250 studentsfrom abroad. With sciences. Itsworldrep-ed toagriculturalfoodandforestry (now research early. Professor Remaclecreated AAT in1999 one ofthelaboratoriestoembarkinPCRandDNA and sciencethecomputersciencesinstitute.Thisled especiallythefacultiesofmedicine various departments, 4,000 studentsandenablescloseconnectionsbetween The The PoleGembloux–Namur The non-profit organization H-Phar. Euroscreen, DelphiGenetics, Aliwen, DNAVision established intheBiopole,amongwhich BioXpr microarrays. The toxicogenomics dimension skinculture modelingforinvitro toxicologyand biotech company, More recently,field ofbioinformatics. in2005,another production processes. vices, eithertodevelopnewproducts ortoimprove their ty theneedsofcompaniesinregion andtooffer itsser- neighboring incubatorcompany, Wallonia Biotech,toidenti- and theNetherlands.Thecenterworkscloselywithits continuewiththeUnitedKingdom,Germany and willfurther University ofLiegebutalsoinFrance(LilleandGrenoble) and alliances.Strong linkshavebeenestablishedwiththe of applicationcausedBioVallee todeveloppartnerships Closely linkedcutting-edgetechnologiesanddiversefields in thesector. companies financial andadministrativeservicestostart-up ronment, etc.Thecenteralsoprovides scientific,logistic, many sectorsofactivity:health,agri-food,agriculture, envi- and analysis,tworapidlyexpandingfieldsthatinvolve (UMH) andIgretec. Itspecializesingeneticconstruction the UniversityofBrussels(ULB),Mons BioValleestart-ups. wasfoundedin2001attheinitiativeof services thatcanbethenmarketedtoorbythenearby ofresearchformation results intoinnovatingproducts and University ofNamur University ofGembloux EAT , founded in 2003, provides expert servicesinthe , foundedin2003,provides expert ) totackletheneedforadvancedandaffordable Straticell (FUNDP) comprisesmore than BioVallee was created, performing three- was created, performing (FUSAGx) ismostlydedicat- facilitates thetrans- Henogen, or created, namely, industrial processes. Asaresult, severalcompanieswere which exploitsmicrobiological diversitytodevelopgenuine ULg inthe“ in thisfieldEurope. TheFUSAGxiscollaboratingwiththe ogy andcancergenetics. for CancerResearch, activein thefieldofcancerimmunol- ICP alsohousestheBelgianbranchofLudwigInstitute biology.ern the commonconceptsandmethodscharacteristicofmod- made possible,beyondthedifferences amongsubjects,by fruitful exchangesthatare diversity generatesparticularly (ICP) pursuesinvestigationsinagreat varietyoffields.This The world, from themoleculetowholeorganism. approaches toinvestigatethefunctioningofliving and appliedprojects, are usingmolecularandcellbiology Allthesegroups, involvedinbasic ulties anddepartments. (ISV) bringstogether24research groups from different fac- In Louvain-la-Neuve,the and onitsbiomedicalcampusinBrussels. the Many research projects inbiotechnologyare carriedoutat The PoleofLouvain-laNeuve Artechno Technologies, CorisBioConcept,Biopole,THT, among them,biotechnologyisrepresented by of theparkalready occupiedbyhigh-techcompanies; Crealys coversanarea ofonesquare kilometerwith67% Science Park. the FUSAGXcontributedtocreation ofthe Midway betweenNamurandGembloux,theFUNDP cient againstpost-harvestdiseasesonapplesandpears. which developedbiopesticides(strainofyeast)thatare effi- to evaluatethemilkproduction abilityofcattle,and Progenus teins, aminoacidsorpotentialtherapeuticagents, tools topredict thetridimensionalstructure ofdifferent pro- These companiesare More recently, severalspin-off companieswere developed. Microbelcaps the UniversityofGhent-RUG), University ofLouvain Christian deDuveInstituteofCellularPathology and which developedagene-baseddiagnostictool Centre Wallon desBio-Industries . Lambda-Plus Agrostar,THT, Artechno,Avecon Biosiris Institut desSciencesdelaVie (UCL), bothinLouvain-la-Neuve . Biotreatment which offers bioinformatics and Crealys Aseptic ” (CWBI), Bionext (with 33 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page34 34 Biotech in Wallonia - Report 2005 Technology ParkofSeneffe, afewkilometres from theUCL. ofresearchment interms funding.IBtisbasedinthe oftheWalloniaIBA andthestrong support Regiongovern- of theexcellenceintechnologyUCL,presence of who choseWallonia asthebasefortheircompanybecause cancers (prostate). IBtwasfoundedbyfourUSscientists a worldleaderinradioactiveimplantsforthetreatment of supplier ofcyclotrons to in closecooperationwiththeUCLandalsoactsasakey 1998 andisacomponentoftheBel-20index.Itstillworks IBA hasbeenlistedontheEuroNext stockexchangesince around theworld. 1500 employeesworkin49locations12countries was 2003, itsannualturnover become worldleaderincyclotrons andproton therapy. In of theUCLCyclotron Research Centre andhasgrown to In 1986, IBA: agrowingleader testing team. selected Louvain-La-NeuveScienceParkforitsR&Dand Solutions Engineering, Enzymes&Derivates,CreativeResearch havejoinedtheparkincluding smaller start-ups Animal Health,SankyoPharma Application sented bysuchwell-knownnamesas in R&Dandproduction. Thefieldoflifesciencesisrepre- More than120high-techcompaniesemploy4,300people Louvain-la-Neuve SciencePark. asdemonstratedbythesuccessoftheir2.25km_ industry and continuestodevelopastrong relationship withthe The University ofLouvain Ion Beam Application and (IBA), Realco Abbott, Ajinomoto, EliLilly, Pfizer . Recently, International Brachytherapy (UCL) hasalwaysmaintained € (IBA) beganasaspin-off 257.7 million.More than and Bayer CropScience Wyeth Ion Beam . Additional Wetlands (IBt), PHOTO : Langerhans isletsinvitro(LaboratoiredeBiologiecellulaire,UCL) Langerhans T505543int 17/10/05 14:42 Page 35 32

EXCELLENCE IN INCENTIVES

“Science and knowledge are like a beautiful engine, but money is like the fuel to get it running!”

Wallonia features a biotechnology sector in which the quali- Energy (DGTRE) and the Wallonia Export and Foreign ty of the scientists and the financial incentives are very Investment Agency (AWEX). attractive. Evaluating and funding scientific projects is the task of the Innovation comes through renewed commitment and DGTRE. Companies can ask the DGTRE to share the risk actions in research. of investing in innovative research and development. The experienced staff at the DGTRE has designed a com- The universities often generate cutting-edge ideas, which prehensive series of financial incentives and subsidies to find fertile ground in the new start-up companies. meet the needs of companies from start-ups to established enterprises. This is a real engine of growth for the sector in So when the Wallonia Region government put biotechnolo- Wallonia and a strong stimulant for companies to exploit gy on the top of its priority list, it was not just on paper, it research results. also meant that real funds were made available to start The first set of incentives is managed by a team dedicated companies, to finance innovative research and to develop to exploiting results from research programs within universi- promotional tactics and strong international partnerships. ties and enterprises. The most popular is the “recoverable advance”, an interest-free loan that covers up to 70% of Thus the money is there, and even more - the people to help you in your project evaluation, in your international expansion and in your search for global partners. Wallonia Tableau 13 entrepreneurs have always looked beyond the country’s Wallonia Region support in biotech applied research (in € million) frontiers to export their innovative products and advanced

technology. Year Entreprises Universities Total

2000 11.8 11.5 23.3 This export-oriented culture and a central location in Europe are clear advantages for any company based in the 2001 7.7 17.6 25.3 region. 2002 7.2 30.1 37.3

The two Wallonia government agencies in conjunction with 2003 9.4 14.3 23.7 a strong financial arm (the SRIW) work in synergy to active- 2004 14.2 19.4 33.6 ly increase the odds of success of any new venture: the Directorate General of Technology, Research and

35 T505543int 17/10/0514:42Page36 36 Biotech in Wallonia - Report 2005 the Created in1979, restructuring process. eign investorsfortheacquisitionofindustrialsitesundera in Wallonia. Inaddition,itisinchargeofidentifyingnewfor- pro-active follow-upservicetoinvestorsalready established tion topotentialforeign investors.TheAgencyalsooffers a Wallonia. Thisincludesseekingoutandproviding informa- eral responsibility ofattractingforeign investmentto tures. Asaforeign investmentagency, AWEX hasthegen- jointven- andinternational designed topromote exports The AWEX provides awiderangeoffinancialincentives expansionofWalloon-basedfor international companies. Through the sistently risingoverthepastyearsasshownintable13. research anddevelopmentinbiotechnologyhasbeencon- The totalamountspentbytheWallonia Regiontosponsor a budgetof cine. Thetotal2002Waleo budgetwas advances intechnologiesthatdirectly benefithumanmedi- “Waleo” isthelatestcampaignthatcoversrecent into thelatesttechnologyfields. the pioneersinspecialdomains.Thisenablesearlyentry larly tailorsfunding“programmes” thatmeettheneedsof common changesinbiotechnology. Consequently, itregu- directed towards thelongterm. are attributabletoactivities whicharepartners principally The financialresources whichtheSRIWgroup bringstoits tion orgrowth ofthecompaniesconcerned. inprojects forredeployment,They participate moderniza- economic developmentoftheWalloon Region. the objectiveofpromoting eitherdirectly orindirectly the financingtocompaniesinBelgium andabroad, with term The capitalises onitbytransferringintoindustry. increasing thescientificpotentialwithinlaboratoriesand researchers Itaimsat inuniversities or youngstart-ups. covers research of expensesincluding100%ofthesalary demic appliedresearch. Theirseriesofsubsidiesusually intheDGTREismore focusedonaca- Another department grants forfeasibilitystudiesandtechnologytransfer. percentage ofproduct sales.Otherpossibilitiesinclude prises. Itisreimbursable asanannualfeerepresenting a applied ordevelopmentresearch expenditure oftheentre- SRIW Group DGTRE € AWEX team closelymonitorstherapidadvancesand 20 millionisplannedforthe2005campaign. , themissionofwhichistoprovide long- SRIW , regional authoritiesoffer strong support and itssubsidiariestogetherform € 17.4 millionand and Oncomethylome Sciences,Probiox,Quality Assistance Henogen, HorpiSystems,H-Phar, KitoZyme, Biopole, BioXpr, BioXtract,Cardio3,Eurogentec, among which: invested in23companiesfrom theLifeSciencesSector, Since 2000,SRIW, Technowal anditssubsidiarieshave New Technologies andEcotechFinanceforenvironment. cific sectors,suchasTechnowal andCDTechnicom for series of“SpecificDevelopmentCenters”inchargespe- To fulfillitsmissionsmore efficiently, theSRIWcreated a ered bytraditionalbankers. financingcov- contrasts withtheconventional,short-term This subordinated orseniorloan,warrants,andsoforth. loans, ornon-convertible convertible equity participations, appropriate solutionisapplied;thesolutionsincludedirect cases. Eachproject isspecificallystudiedandthemost The flexibilityoftheSRIWenablesittoadaptindividual the creation of ❚ fast-growing companiesandsomeuniversityfunds. the biotechandhightechsectors, Start-It ❚ Besides itstraditionalcore activities,theSRIW: ig MeusInvest InvestSud Namur NamurInvest Investmentcompany Liège SambreInvest Invest BorinageCentre Luxembourg HoccInvest part Hainaut Central&Eastern part Hainaut Southern part Hainaut Western Province rbn alnNivelInvest OstBelgienInvest Community Liège German Brabant Wallon The localpublicinvestmentcompanies Tableau 14 has expandedoutsidethecountry’s boundaries through inthecreation of severalVCfunds,i.e. has participated Zentech , dedicated to investment in start-up companiesin , dedicatedtoinvestmentinstart-up , foratotalinvestmentofnearly Aseptic Technologies, BiocodeHycel, Cossom , a subsidiary handlingforeign inter- , asubsidiary E-Capital € targeted at 50 million. T505543int 17/10/0514:42Page37 ups, suchasfeasibilityandmarket studies,aswellstud- finance stagespreceding the establishment ofnewstart- ment company, The UniversityofLiege,incooperationwiththelocalinvest- stage financingforhightechnologycompanies. ated withpublicandinstitutionalinvestorstoprovide early BrachyTherapy nies played akeyrole inthedevelopmentoflistedcompa- incubator.and technologytransfercompanyvirtual It The UniversityofLouvainsetup their ownventure capitalfund. onsuchinvestments,mostofthemhavesetup best return additional wealththrough spin-off companies.To getthe intheeconomyastheynowcreate tists, activelyparticipate and nourishestheemploymentmarketwithtrainedscien- quality educationthatfulfillstheir“social”role insociety The universitiesthemselves,inadditiontoproviding high investment companies. funds togetherwithuniversitiesandlocalregional inmixed financing. Inaddition,theseinvestorsparticipate biotechnology companiesthrough equityormezzanine KBC Investco,DexiaVentures… tional investors( Mara Ventures low-up capital.Specializedventure capitalfundssuchas companiestoraiseseed,earlystageorfol- help start-up Venture capitalfundingisavailablefrom privatefundsthat and onstrong universitysupport. pool ofprivateventure capitalistsandprivateequityfunds Wallonia canalsocountonanactiveandrapidlygrowing To obtainitsrequired funding,thebiotechnologysectorin ulus tothebiotechnologycommunity. Region offers andstim- anefficient combinationofsupport aspects andtheSRIWmanaginginvestments,Wallonia With theDGTREinchargeofresearch andscientific sequential investmentsforrapidlygrowing companies. funds tograntsubstantialfinancingrounds andtosecure ❚ and withuniversityfundsforseedcapital. cial investmentcompaniesproviding earlystagefinancing ❚ national investments. networks regularly withventure capitalandprivateequity works activelyincooperationwiththeeightlocalprovin- Ion Beam Applications or privateequityfundsfrom largeinstitu- MeusInvest ING PrivateEquity, FortisPrivateEquity, (IBt). Italsomanagesthe , created (IBA) and Sopartec ) support Wallonia) support Spinventure International , aseedcapital Vives fund, cre- to have jointlycreated the the UniversityofMonsandPolytechnicFaculty issued from academicresearch oftheinstitution.Similarly, Theodorus In recent years,theUniversityofBrusselshascreated the stage, italsooffers seedcapital. ies onindustrializationandcommercialization. Initssecond be sustainedthecomingyears. rently remarkable rateofcreation ofspin-offs isexpectedto talizing onresearch conductedwithintheirlabs,thecur- ofcapi- As universitieskeeponconsideringtheimportance Valorisation University ofGemblouxhascreated fund toprovide seedfinancingtothespin-offs for thesamepurposes. IMBC-Spinnova Gembloux fund, andthe 37 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page38 38 Biotech in Wallonia - Report 2005 We welcomeyoutojoinusandgeneratewelfaretogether. We inviteyoutoparticipateinthisprocessofvaluecreation. The regionisprovingitsabilitytoturnpromisesintosuccesses. Wallonia hasbecomeamasterofcreation,innovationandknowledge. Recent yearshaveshownthegreatpotentialandrichnessinregion. from 3,000fiveyearsago(largeandentrepreneurialcompaniestogether). future and investment ineducation,itbringshighlyeducatedandspecializedyoungsterstotheworkplace,givingthemhopefor the Wallonia cancreate employment. 2,376millioninatwoyearperiod. 1,994millionto nal product”issuedfromthebiotechnologyactivitythatgrew Wallonia cancreate wealth. the regionplaceitselfintopranksEurope. staggering progressionofthenumberenterprisesactiveinbiotechnologysector, from55in2001to692003,helps Wallonia hasproven itsabilitytoexploitthebestopportunitiesandfruitsarisingfrominnovativeresearch nies havefoundafertileenvironmentforrapidexpansionandambitiousnewdevelopmentprograms. authorities andlocalindustrytobeextremelyhelpfulinsettingupabasestarttheiractivity. Consequentlymanycompa- exploit thefantasticresultsfromresearchlaboratoriesbasedinuniversities.Entrepreneurshavefoundregional Biotechnology stronglyremainsatthetopofregion’s prioritylist. The sectorcontinuestoboomandopportunitiesariset millennium withadecisivecommitmenttosupportknowledge-basedeconomy. With excellenceinhumanresourcesandresearch,financialincentivesgrants,Wallonia hasenteredthethird real employment opportunities. Today, thebiotechsectoremploysclose to 5,000scientistsandtechnicians,up This strategyofstimulatingthesectorincreasesregion’s wealthasshownbya“grossregio- Hard hitintheearly1970s,regioncanreconstructitselfandthankstoitsintelligent TIME TOHARVEST . Indeed,the o T505543int 17/10/0514:42Page39 P HOTO : Carbon nanotubemodeling(FUNDP-RMN -LISE) 39 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page40 40 Biotech in Wallonia - Report 2005 & Research and Development QualityControl PolylacticAcid Positron Emission Tomography R&D PersonalDigital Assistant QC Polymerase ChainReaction PLA PET PolychlorinatedBiphenyls SpecificPCR Methylation PDA PCR LiquidChromatography HighPerformance In Vitro Diagnostic PCB’s HumanPapillomaVirus MSP HumanImmune-DeficiencyVirus HPLC HepatitisBVirus IVD HPV G-Protein CoupledReceptors GoodManufacturing Practice HIV FrameworkProgram Sixth HBV Fluorodeoxyglucose GPCR Ear, NoseandThroat GMP Electronic DataCapture FP6 DeoxyriboNucleicAcid FDG ContractResearch Organization ENT EDC ContractManufacturingOrganization DNA Current GoodManufacturingPractice CRO Acquired Immune-Deficiency Syndrome CMO cGMP AIDS Terms Abbreviations USEFUL INFORMATION T505543int 17/10/0514:42Page41 H World HealthOrganization NationsChildren's United Fund Techno-High-Technology SociétéRégionaled’Investissement deWallonie Gent Universiteit WHO Recherche IndustrieThérapeutique Rheinisch-Westfälischen Technische HochschuleAachen UNICEF PanAmericanHealthOrganization THT OncoMethylomeSciences SRIW Limburgs UniversitairCentrum RWTH-Aachen Institut desSciencesdela Vie RUG Institute ofMedicalImmunology RIT Institute ofCellularPathology PAHO InstituteofBiologyandMolecularMedicine OMS BrachyTherapy International LUC Ion BeamApplication ISV IMI Groupement Interdisciplinaire deGénoprotéomique Appliquée ICP USFoodandDrugAdministration IBMM Biologicals GlaxoSmithKline Eurogentec IBt ArrayTechnology Eppendorf IBA GSK Biologicals GeneralDirectorate forTechnology, Research andEnergy Centre Wallon desBio-Industries GIGA Centre deRecherche surlesProtéines Prion FDA Centre deRecherche Interuniversitaire enVaccinologie EGT EAT Research Centerforthe ManagementofBio-industries Centre forProtein Engineering DGTRE Centre desBiomatériaux Interfacultaire CWBI Centre ofBiomedicalIntegrativeGenoproteomics CRPP Centre d'analysedesrésidusentraces CRIV Centre d'Economierurale CRGB Wallonia andForeign InvestmentAgency Export CIP AdvancedArrayTechnologies CEIB CBIG CART CER AWEX AAT Venture Capitalist Companies andinstitutions Transmission Technical Control Protocol Protocol/Internet Analysis SyncytialVirus Respiratory VC TCP/IP TA RSV 41 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page42 42 Biotech in Wallonia - Report 2005 +32 (0)43664394 [email protected] http://www.giga.be.ulg.ac.be B-4000 Liège B23 Avenue del'hôpital,3 ClusterforApplied Genoproteomics GIGA -Interdisciplinary +32 (0)84220211 [email protected] http://www.province.luxembourg.be/agriculture/cer.html B-6900 Marloie Rue duCarmel,1 CER –Centred’EconomieRurale +32 (0)71378500 [email protected] http://www.biovallee.be B-6041 Gosselies Rue desProfesseursJeeneretBrachet,12 BIOVALLEE ASBL + 32(0)43665227 [email protected] http://www.bioliege.ulg.ac.be B-4000 Liège Place du20Août,7 BIOLIEGE ASBL UniversitédeMons-Hainaut–UniversityofMons UniversitéLibre deBruxelles–UniversityofBrussels Academic &research deLiège–University ofLiège Université Main Addresses UniversitéCatholiquedeLouvain–Universityof FacultésUniversitaires Notre-Dame delaPaix–UniversityofNamur FacultésUniversitaires desSciencesAgronomiques deGembloux-Universityof UMH FacultésUniversitaires CatholiquesdeMons ULB FacultésUniversitaires Saint-Louis FacultéPolytechniquedeMons ULg UCL FUNDP FUSAGx FUCaM FUSL FPMs Universities inWallonia Gembloux +32 (0)81622111 [email protected] http://www.fsagx.ac.be B-5030 Gembloux Passage desdéportés2 de Gembloux FUSAGx -FacultéUniversitairedesSciencesAgronomiques +32 (0)81725032 [email protected] http://www.fundp.ac.be B-5000 Namur Rue deBruxelles53 FUNDP -FacultésUniversitairesNotre-DamedelaPaix +32 (0)65374496 [email protected] http://www.fpms.ac.be B-7000 Mons Rue del'Epargne56 FPMs -FacultéPolytechniquedeMons +32 (0)26509560 [email protected] http://www.ulb.ac.be/imi/homepage.html B-6041 Gosselies Rue A.Bolland8 IMI -InstituteofMedicalImmunology +32 (0)71378611 http://www.ulb.ac.be/ibmm B-6041 Gosselies Rue desProfesseursJeeneretBrachet12 IBMM -InstituteofBiologyMolecularMedicine T505543int 17/10/0514:42Page43 +32 (0)43662861 [email protected] http://www.ulg.ac.be/cwbi B-5030 Gembloux Passage desdéportés2 CWBI -Walloon CentreofIndustrialBiology +32 (0)10390021 [email protected] http://www.sopartec.com B-1348 LouvainLaNeuve Chemin duCyclotron,6 SOPARTEC +32 (0)65373001 [email protected] http://www.umh.ac.be/index.html B-7000 Mons Place duParc20 UMH -UniversitédeMons-Hainaut +32 (0)43662111 [email protected] http://www.ulg.ac.be B-4000 Liège Place duXXAoût9 ULg -UniversitédeLiège +32 (0)26503204 [email protected] http://www.ulb.ac.be B-1050 Brussels Avenue F. D.Roosevelt,50,CP161 ULB -UniversitéLibredeBruxelles +32 (0)10472111 [email protected] http://www.ucl.ac.be B-1348 Louvain-La-Neuve Place del'Université1 UCL -UniversitéCatholiquedeLouvain +32 (0)81626555 [email protected] http://www.cra.wallonie.be B-5030 Gembloux Rue deLiroux9 GEMBLOUX AGRICULTURAL RESEARCHCENTRE +32 (0)81601943 [email protected] http://www.artechno.be B-5030 Gembloux Rue FrançoisBovesse,1 ARTECHNO +32 (0)10228384 [email protected] http://www.agrostar-sa.com B-5000 Namur Rue JeanNöel25 AGROSTAR Environment +32 (0)26550821 [email protected] http://www.phibroah.com B-1330 Rixensart Rue del'Institut87A PHIBRO +32 (0)26568960 [email protected] http://www.gsk.com B-1330 Rixensart Rue del'Institut,89 GLAXOSMITHKLINE BIOLOGICALS +32 (0)254884 http://www.lilly.be B-1000 Brussels Rue del’étuve52B1 ELI LILLY BENELUX +32 (0)43642400 [email protected] http://www.dyax.com B-4000 Liège Sart Tilman, BuildingB22 Boulevard duRectorat27B DYAX +32 (0)68272211 http://www.baxter.be B-7860 Lessines Boulevard RenéBranquart80 BAXTER Biopharmaceuticals 43 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page44 44 Biotech in Wallonia - Report 2005 [email protected] http://www.analis.be B-5000 Namur Rue Dewez14 ANALIS Medical devices/diagnostics +32 (0)10861525 [email protected] http://www.wetlands.be B-1348 LouvainLaNeuve 5, rueduLaidBurniat WETLANDS ENGINEERING +32 (0)42526602 [email protected] http://www.unisensor.be B-4000 Liège Rue E.Solvay27b UNISENSOR +32 (0)10453000 [email protected] http://www.realco.be B-1348 LouvainLaNeuve Avenue Albert Einstein15 Parc ScientifiqueEinstein REALCO +32 (0)42407500 [email protected] http://www.quality-partner.be B-4040 Herstal Rue Hayeneux62 QUALITY PARTNER +32 (0)71256041 [email protected] http://www.ecoterres.be B-6041 Gosselies Aéropole Avenue JeanMermoz3C ECOTERRES + 32(0)43729220 [email protected] http://www.Biorem.be B-4122 Plainevaux Route duCondroz,6 BIOREM +32 (0)81725613 [email protected] http://www.aat-array.com B-5000 Namur Rue duSéminaire20A EPPENDORF ARRAY TECHNOLOGIES +32 (0)43666100 [email protected] http://www.eurogentec.com B-4102 Seraing Rue duBoisSaint-Jean14 Parc ScientifiqueduSart-Tilman EUROGENTEC +32 (0)65841888 [email protected] http://www.d-tek.be B-7000 Mons Rue Brisselot11 D-TEK +32 (0)68551482 [email protected] http://www.diagam.com 7822 Ghislenghien Rue duParcIndustriel DIAGAM +32 (0)81719917 [email protected] http://www.corisbio.com B-5032 Gembloux Rue PhocasLejeune,30B9 Parc ScientifiqueCrealys CORIS BIOCONCEPT +32 (0)678899 http://www.biosource.com B-1400 Nivellles Rue del'Industrie8 BIOSOURCE EUROPE +32 (0)42522636 [email protected] http://www.biocode.be B-4000 Liège Rue ErnestSolvay101-103 BIOCODE –HYCEL +32 (0)812550 T505543int 17/10/0514:42Page45 [email protected] http://www.beldem.be B-5300 Andenne Zoning IndustrieldeSeilles,RueBourrie 12 BELDEM Novel foodandingredients +32 (0)43614232 [email protected] http://www.zentech.be B-4031 Angleur Avenue Pré Aily10 Parc ScientifiqueSartTilman ZENTECH +32 (0)43665227 [email protected] http://www.probiox.com B-4000 Liège Place du20-Aout4 PROBIOX +32(0)4 3669860 [email protected] http://www.oncomethylome.com B-4000 Liège Avenue de l’Hôpital1 ONCOMETHYLOME SCIENCES +32 71823568 http://www.mds.nordion.com B-6220 Fleurus Avenue del'Espérance Zoning Industriel MDS NORDION +32 (0)64520811 [email protected] http://www.ibt.be B-7180 Seneffe Zone IndustrielleC INTERNATIONAL BRACHYTHERAPY +32 (0)436140 [email protected] http://www.gamma.be B-4031 Angleur Rue desChasseursArdennais Parc ScientifiqueduSart-Tilman GAMMA +32 (0)42598500 [email protected] http://www.kitozyme.com B-4031 Angleur Avenue PréAily Centre Socran KITOZYME +32 (0)69451400 [email protected] http://www.lactic.com B-7760 Escanaffles Place d'Escanaffles23 GALACTIC +32 (0)10486466 [email protected] B-1348 Louvain-La-Neuve Rue duBosquet7 Parc Scientifique ENZYMES &DERIVATES BELGIUM +32 (0)42599330 [email protected] http://www.enzybel.be B-4530 Villers-Le-Bouillet Rue deWaremme 116B ENZYBEL +32 (0)69446600 [email protected] http://www.cosucra.com B-7740 Warcoing rue delaSucrerie1 COSUCRA GroupeWarcoing +32 (0)81723460 [email protected] http://www.biopole.com/ B-5032 Gembloux(LesIsnes) Rue HermanMeganck21 BIOPOLE +32 (0)61240540 [email protected] http://www.belovo.com B-6600 Bastogne Rue d'Assenois1 Zoning Industriel BELOVO +32 (0)85823250 45 Biotech in Wallonia - Report 2005 T505543int 17/10/0514:42Page46 46 Biotech in Wallonia - Report 2005 [email protected] http://www.arlenda.com B-4000 Liège Avenue del'hôpital,1BâtB36 ARLENDA +32 (0)42461506 [email protected] http://www.affiland.com B-4430 Liège 304 ruedel'Yser AFFILAND &TechServices providers +32 (0)43663906 [email protected] http://www.phytesia.com B-4000 Liège Boulevard duRectorat27B22 PHYTESIA +32 (0)80215793 [email protected] http://www.bioplant.be B-6698 Grand-Halleux Rue EysdenMines43A BIOPLANT INVITRO Plant breeding +32 (0)81569280 [email protected] http://www.tht.be B-5032 Isnes Rue PhocasLejeune30 Parc ScientifiqueCréalys TECHNO HIGHINDUSTRY (THT) +32 (0)81616901 [email protected] http://www.progenus.be B-5030 Gembloux 13 Avenue MaréchalJuin PROGENUS [email protected] http://www.biosiris.com B-5032 Gembloux Rue PhocasLejeune,30-Bte17 Science ParkCREALYS -Cassiopée BIOSIRIS +32 (0)65401676 [email protected] http://www.biochem-europe.com B-7000 Mons Boulevard Initialis5 BIOCHEM EUROPE +32(0)71 348500 http://www.euroscreen.be B-6041 GOSSELIES Rue AdrienneBolland47 EUROSCREEN +32 (10)4211 [email protected] http://www.sgsbiopharma.com B-1301 Wavre Vieux CheminduPoète110 SGS BIOPHARMA +32 (0)71378501 [email protected] http://www.dnavision.be B-6041 Gosselies Rue AdrienneBolland8 DNA VISION +32 (0)71378525 [email protected] http://www.delphigenetics.com B-6041 Gosselies Rue AdrienneBolland8 DELPHI GENETICS +32 (0)81725155 [email protected] http://www.bioxpr.be B-5000 Namur Rue duséminaire,22 Centre technologiqueFUNDP BIOXPR +32 (0)81713430 +32 (0)43664397 T505543int 17/10/0514:42Page47 [email protected] http://www.activemotif.com B-1330 Rixensart Avenue FranklinRoosevelt104B25 ACTIVE MOTIFEUROPE Research Biologicals +32 (0)255999 http://www.ucb-group.com B-1070 Brussels Allée delaRecherche,60 UCB BIOPRODUCTS +32 (0)42407500 [email protected] http://www.quality-assistance.com B-6536 Donstiennes Technoparc deThudinie1 QUALITY ASSISTANCE +32 (0)43662861 [email protected] http://www.microbelcaps.com B-4000 Liège Rue Simonon8 Sart-Tilman BâtimentB40 MICROBELCAPS +32 (0)81560178 [email protected] http://www.lambdaplus.com B-5032 Isnes Créalys ScienticPark,RueCamilleHubert5 LAMBDA PLUS +32(0)71 378902 [email protected] www.henogen.com B-6041 Gosselies Rue desProfesseursJeeneretBrachet12 HENOGEN +32 (0)23530028 [email protected] http://www.floridienne.be/contact.html B-1410 Waterloo Chaussée deTervuren 198f FLORIDIENNE +32 (0)26530001 [email protected] http://www.cambrex.com B-4800 Verviers Parc IndustrieldePetit-Rechain CAMBREX BIOSCIENCE +32 (0)43663100 http://www.eurogentec.com B-4102 Seraing Rue duBoisSaint-Jean5 EUROGENTEC http://mrw.wallonie.be/dgtre B-5100 Jambes Avenue Prince deLiège7 DGTRE -DirectorateGeneralofTechnology, ResearchandEnergy +32 (0)26460564 http://www.bba-bio.be B-1050 Brussels Avenue GuillaumeVan Leeuw14 BBA -BelgianBioindustriesAssociation +32 (0)423011 [email protected] http://www.spi.be B-4000 LIEGE 11 RueduVertbois SPI + +32 (0)42219811 http://www.sriw.be B-4000 Liège Avenue Destenay 13 SRIW +32 (0)24218211 http://www.awex.be B-1080 Brussels Place Sainctelette2 AWEX -WALLONIA EXPORT ANDFOREIGNINVESTMENTAGENCY +32 (0)87321611 Agencies andassociations +32 (0)813350 47 Biotech in Wallonia - Report 2005 T505543int 17/10/05 14:42 Page 48

DGTRE - DIRECTORATE GENERAL OF TECHNOLOGY, RESEARCH & ENERGY

Ministry of Wallonia Region

Av. Prince de Liège, 7

B - 5100 Namur (Belgium)

Tel +32-81-33 50 50

Fax +32-81-30 66 00

http://mrw.wallonie.be/dgtre/biotech

Copyright Wallonia Region – DGTRE Brochure updated by the Centre PME, Pi2 & the CRGB of the University of Liege and DGTRE

Design geluck, suykens & partners